Literature DB >> 10462762

GPCR-Galpha fusion proteins: molecular analysis of receptor-G-protein coupling.

R Seifert1, K Wenzel-Seifert, B K Kobilka.   

Abstract

The efficiency of interactions between G-protein-coupled receptors (GPCRs) and heterotrimeric guanine nucleotide-binding proteins (G proteins) is greatly influenced by the absolute and relative densities of these proteins in the plasma membrane. The study of these interactions has been facilitated by the use of GPCR-Galpha fusion proteins, which are formed by the fusion of GPCR to Galpha. These fusion proteins ensure a defined 1:1 stoichiometry of GPCR to Galpha and force the physical proximity of the signalling partners. Thus, fusion of GPCR to Galpha enhances coupling efficiency can be used to study aspects of receptor-G-protein coupling that could not otherwise be examined by co-expressing GPCRs and G proteins as separate proteins. The results of studies that have made use of GPCR-Galpha fusion proteins will be discussed in this article, along with the strengths and limitations of this approach.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10462762     DOI: 10.1016/s0165-6147(99)01368-1

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  28 in total

1.  Preparation of unnatural N-to-N and C-to-C protein fusions.

Authors:  Martin D Witte; Juan J Cragnolini; Stephanie K Dougan; Nicholas C Yoder; Maximilian W Popp; Hidde L Ploegh
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-09       Impact factor: 11.205

Review 2.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

3.  Galpha subunit Gpa2 recruits kelch repeat subunits that inhibit receptor-G protein coupling during cAMP-induced dimorphic transitions in Saccharomyces cerevisiae.

Authors:  Toshiaki Harashima; Joseph Heitman
Journal:  Mol Biol Cell       Date:  2005-07-19       Impact factor: 4.138

4.  Interaction of fenoterol stereoisomers with β2-adrenoceptor-G sα fusion proteins: antagonist and agonist competition binding.

Authors:  Michael T Reinartz; Solveig Kälble; Irving W Wainer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2015-01-31       Impact factor: 3.000

5.  Point mutations in the second extracellular loop of the histamine H2 receptor do not affect the species-selective activity of guanidine-type agonists.

Authors:  Hendrik Preuss; Prasanta Ghorai; Anja Kraus; Stefan Dove; Armin Buschauer; Roland Seifert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2007-11-13       Impact factor: 3.000

6.  Measurement of thyroid stimulating immunoglobulins using a novel thyroid stimulating hormone receptor-guanine nucleotide-binding protein, (GNAS) fusion bioassay.

Authors:  M Pierce; R Sandrock; G Gillespie; A W Meikle
Journal:  Clin Exp Immunol       Date:  2012-11       Impact factor: 4.330

7.  Regulation of the avidity of ternary complexes containing the human 5-HT(1A) receptor by mutation of a receptor contact site on the interacting G protein alpha subunit.

Authors:  Philip J Welsby; I Craig Carr; Graeme Wilkinson; Graeme Milligan
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Coupling specificity of NOP opioid receptors to pertussis-toxin-sensitive Galpha proteins in adult rat stellate ganglion neurons using small interference RNA.

Authors:  Wojciech Margas; Khaled Sedeek; Victor Ruiz-Velasco
Journal:  J Neurophysiol       Date:  2008-06-18       Impact factor: 2.714

9.  Allosteric theory: taking therapeutic advantage of the malleable nature of GPCRs.

Authors:  Terry Kenakin
Journal:  Curr Neuropharmacol       Date:  2007-09       Impact factor: 7.363

10.  Allosteric communication between protomers of dopamine class A GPCR dimers modulates activation.

Authors:  Yang Han; Irina S Moreira; Eneko Urizar; Harel Weinstein; Jonathan A Javitch
Journal:  Nat Chem Biol       Date:  2009-08-02       Impact factor: 15.040

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.